Plasticity of Lineage Switch in B-ALL Allows for Successful Rechallenge with CD19-directed Immunotherapy

Overview

Journal Blood Adv

Specialty Hematology

Date 2023 Feb 10

PMID 36763522

Authors

Brittany M Lee

Corinne Summers

Karen M Chisholm

Sandra D Bohling

Kasey J Leger

Rebecca Gardner

Colleen Annesley

Adam J Lamble

Affiliations

Soon will be listed here.

Citing Articles

The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients.

Qiu S, Mei Y, Gu R, Liu Y, Chen M, Xing H Leukemia. 2024; 39(1):238-242.

PMID: 39482352 DOI: 10.1038/s41375-024-02449-7.

-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy.

Silbert S, Scanlon S, Wang H, Yuan C, Doverte A, Wellek J J Immunother Cancer. 2024; 12(10).

PMID: 39461880 PMC: 11529463. DOI: 10.1136/jitc-2024-009499.

How I treat postimmunotherapy relapsed B-ALL.

Lamble A, Kovach A, Shah N Blood. 2024; 145(1):64-74.

PMID: 39046821 PMC: 11738038. DOI: 10.1182/blood.2024024517.

References

Pui C, Chessells J, Camitta B, Baruchel A, Biondi A, Boyett J . Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia. 2003; 17(4):700-6. DOI: 10.1038/sj.leu.2402883. View

van der Velden V, Corral L, Valsecchi M, Jansen M, de Lorenzo P, Cazzaniga G . Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia. 2009; 23(6):1073-9. DOI: 10.1038/leu.2009.17. View

Mejstrikova E, Hrusak O, Borowitz M, Whitlock J, Brethon B, Trippett T . CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 2017; 7(12):659. PMC: 5802535. DOI: 10.1038/s41408-017-0023-x. View

Gardner R, Finney O, Annesley C, Brakke H, Summers C, Leger K . Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017; 129(25):3322-3331. PMC: 5482103. DOI: 10.1182/blood-2017-02-769208. View

Shah B, Ghobadi A, Oluwole O, Logan A, Boissel N, Cassaday R . KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021; 398(10299):491-502. PMC: 11613962. DOI: 10.1016/S0140-6736(21)01222-8. View

Kuo A, Paulson V, Hempelmann J, Beightol M, Todhunter S, Colbert B . Validation and implementation of a modular targeted capture assay for the detection of clinically significant molecular oncology alterations. Pract Lab Med. 2020; 19:e00153. PMC: 7038441. DOI: 10.1016/j.plabm.2020.e00153. View

Moskop A, Pommert L, Baggott C, Prabhu S, Pacenta H, Phillips C . Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Adv. 2022; 6(14):4251-4255. PMC: 9327536. DOI: 10.1182/bloodadvances.2021006393. View

Wolfl M, Rasche M, Eyrich M, Schmid R, Reinhardt D, Schlegel P . Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in -rearranged infant ALL. Blood Adv. 2018; 2(12):1382-1385. PMC: 6020817. DOI: 10.1182/bloodadvances.2018018093. View

Lamble A, Myers R, Taraseviciute A, John S, Yates B, Steinberg S . Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2022; 7(4):575-585. PMC: 9979750. DOI: 10.1182/bloodadvances.2022007423. View

10.

Tirtakusuma R, Szoltysek K, Milne P, Grinev V, Ptasinska A, Chin P . Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia. Blood. 2022; 140(17):1875-1890. PMC: 10488321. DOI: 10.1182/blood.2021015036. View

11.

Knez V, Liu X, Schowinsky J, Pan Z, Wang D, Lorsbach R . Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: a multi-institutional study. Leuk Lymphoma. 2018; 60(4):1006-1013. DOI: 10.1080/10428194.2018.1508667. View

12.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

13.

Du J, Chisholm K, Tsuchiya K, Leger K, Lee B, Rutledge J . Lineage Switch in an Infant B-Lymphoblastic Leukemia With t(1;11)(p32;q23); , Following Blinatumomab Therapy. Pediatr Dev Pathol. 2021; 24(4):378-382. DOI: 10.1177/10935266211001308. View

14.

He R, Nayer Z, Hogan M, Cuevo R, Woodward K, Heyer D . Immunotherapy- (Blinatumomab-) Related Lineage Switch of Rearranged B-Lymphoblastic Leukemia into Acute Myeloid Leukemia/Myeloid Sarcoma and Subsequently into B/Myeloid Mixed Phenotype Acute Leukemia. Case Rep Hematol. 2019; 2019:7394619. PMC: 6925828. DOI: 10.1155/2019/7394619. View

15.

Haddox C, Mangaonkar A, Chen D, Shi M, He R, Oliveira J . Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. Blood Cancer J. 2017; 7(9):e607. PMC: 5637108. DOI: 10.1038/bcj.2017.89. View

16.

Zoghbi A, Zur Stadt U, Winkler B, Muller I, Escherich G . Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement. Pediatr Blood Cancer. 2017; 64(11). DOI: 10.1002/pbc.26594. View

17.

Oberley M, Gaynon P, Bhojwani D, Pulsipher M, Gardner R, Hiemenz M . Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia. Pediatr Blood Cancer. 2018; 65(9):e27265. PMC: 7469918. DOI: 10.1002/pbc.27265. View

18.

Rayes A, McMasters R, OBrien M . Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy. Pediatr Blood Cancer. 2016; 63(6):1113-5. DOI: 10.1002/pbc.25953. View